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. For example, in order to support their high rates of proliferation, cancer cells consume additional nutrients and divert those nutrients into macromolecular synthesis pathways (FIG. 1a) . Metabolic pathways must therefore be rewired in such a way that balances biosynthetic processes with sufficient ATP production to support cell growth and survival. As all cancer cells are dependent on this change in metabolism, these altered pathways represent attractive therapeutic targets 2, 3 . However, because normal prolifer ating cells have the same metabolic requirements as cance r cells, finding a therapeutic window between pro liferating cancer cells and proliferating normal cells remains a major challenge in the development of successful cancer therapie s targeting metabolic pathways.
Unlike their normal counterparts, many cancer cells metabolize glucose by aerobic glycolysis 1, 4, 5 . This phenom enon, known as the Warburg effect, is characterized by increased glycolysis and lactate production regardless of oxygen availability. Aerobic glycolysis is often accom panied by increased glucose uptake, and this phenom enon may be visualized in tumours of patients using 18 F-deoxyglucose positron emission tomography (FDG-PET) imaging. FDG-PET is used clinically as a staging tool for diverse types of cancers, and experimental PET tracers can distinguish cancer cells from normal cells based on other aspects of cancer metabolism 6 . Differential uptake of 11 Ccholine, 11 Cacetate, 11 Cmethionine and 18 Flabelled amino acid analogues has been demonstrated in some human cancers 6, 7 . Variable uptake of these molecules -as well as FDG -and variable secretion of lactate are all observed in cancers, even among tumours arising from the same tissue [6] [7] [8] [9] . Why some cancers exhibit increased labelling with these tracers is not understood; however, these findings suggest that tumours exhibit heterogeneous metabolic alterations that extend beyond the Warburg effect (FIG. 1b) . Nevertheless, all cancer cells must ultimately direct avail able nutrients into the synthesis of new biomass while maintaining adequate levels of ATP for cell survival. Therefore, it is likely that these phenotypic differences are manifestations of various metabolic solutions that enable the proliferation of cancer cells in individual tumours.
At least some of the metabolic heterogeneity that is observed in tumours is influenced by the tumour microenvironment 5 . Abnormal tumour vasculature can result in gradients of nutrients, oxygen and pH. Glucose, amino acids and lipids provide the substrates to supply metabolic pathways, and therefore metabolism is altered depending on the cellular availability of these nutrients. In addition, the signalling mechanisms of cells are linked to growth control pathways that sense conditions such as amino acid availability and oxygen levels; these signalling mecha nisms also influence metabolism 5, [10] [11] [12] . Genetic alterations that are associated with cancer often occur in these same signalling pathways, which suggests that both environ mental and genetic factors influence the metabolic het erogeneity that is present across tumours 5 . Despite having an indepth understanding of meta bolic regulation, which has been built on almost a century of biochemistry research, our knowledge of how pathways are regulated to facilitate cell proliferation is incomplete 13 .
Success in targeting cancer metabolism will emerge from

Tumour microenvironment
The local conditions experienced by cells in a tumour, including the levels of nutrients, oxygen and signalling molecules such as growth factors and cytokines.
Metabolic enzymes
Proteins that catalyse the interconversion of two metabolites.
a better understanding, in specific genetic contexts, of pre cisely how cells regulate the flux of nutrients into pathways that are required for biosynthesis. Understanding tumour cell metabolism requires the use of methods to assess metabolite flux and pathway regulation that are not often used in cancer drug discovery. However, akin to how anti biotics target the biosynthetic processes that are unique to microorganisms, the possibility of selectively targeting the biosynthetic processes of cancer cells holds promise as a strategy for improving cancer therapy.
Here, we review existing evidence supporting the thera peutic potential of targeting the metabolic adapta tions that are characteristic of cancer cells, discuss the associated challenges and limitations of this as an anti cancer strategy, and outline a framework for consider ing new targets in cancer metabolism. We also discuss emerging evidence involving specific metabolic enzyme targets, and examine how they might be used to limit cell proliferation. To date, only a handful of molecules that target metabolic pathways have been tested as a form of cancer therapy. However a growing body of evidence supports the notion that altered metabolism is a key consequence of important genetic drivers of cancer, thus inciting renewed interest in exploring metabolic enzymes as therapeutic targets.
Why target cancer cell metabolism?
Metabolism may influence cancer initiation and progression. Clinical studies have linked altered wholebody metabolism to cancer development, progression and poor treatment outcomes. Indeed, obesity, hyper glycaemia and insulin resistance are all associated with an increased risk of developing cancer and are associated with worse clinical outcomes in patients with cancer [14] [15] [16] [17] [18] . However, how such changes in organismal metabolism influence metabolism at the cellular level to promote cancer is controversial.
Increased circulating levels of insulin and insulinlike growth factor (IGF) have been linked with cancer pro gression, which suggests that obesity and insulin resistance promote cancer at least in part by activating sig nalling pathways that drive cell growth 15 . These same signalling pathways also drive nutrient uptake into cells and regulate enzymes in glycolysis, which implies that hormonal changes can have important indirect effects on cancer cell metabolism 16 . Furthermore, elevated levels of glucose alone may promote increased glucose uptake in some cells, and lower circulating levels of glucose are associated with bette r cancer treatment outcomes [19] [20] [21] [22] . As a result, antidiabetic drugs are being explored for antitumour activity, and retrospective clinical stud ies have shown a reduction in cancerrelated mortality in patients with diabetes who are taking metformin 23, 24 . However, this effect appears to be independent of blood glucose levels, as patients with diabetes whose blood glu cose levels are controlled by other means do not derive the same anticancer effect as patients taking metformin 24 . Metformin is widely used for the treatment of type 2 dia betes and acts by inhibiting mitochondrial complex I in the liver to interfere with ATP production 25, 26 . This causes energy stress, increased AMPactivated protein kinase (AMPK) activity and inhibition of gluconeogenesis, which results in lower blood glucose levels, improved insulin sensitivity and decreased insulin 27 . Thus, it is controver sial whether metformin benefits patients with cancer by directly acting on the tumour or by indirectly decreasing levels of insulin and insulinrelated growth factors.
Other antidiabetic therapies that act by raising insulin levels may therefore lead to worse clinical outcomes in patients with cancer. Dietary restriction, which has been known to prolong survival in cancer models, has no effect on tumours that proliferate in the absence of IGF signal ling 28 . These findings are consistent with metformin pro viding an indirect benefit to patients with high circulating levels of IGF. However, high doses of metformin are toxic to cancer stem cells 29 , and women taking metformin have an increased tumour response to neoadjuvant chemo therapy for breast cancer that may extend to patients with cancer who do not have diabetes 30 . Figure 1 | Cancer cell metabolism. Proliferating cell metabolism involves a shift in nutrient metabolism towards biosynthesis. a | Mammalian cells are exposed to ~5 mM glucose and ~0.5 mM glutamine in serum, and these nutrients are the primary metabolic fuel for cancer cells and many normal cells. Additional nutrients, including lipids and other amino acids, can also be an important source of ATP and biosynthetic precursors for some cells. Most of the increased nutrient uptake in proliferating cells is used to support biosynthetic reactions. As a result, cancer cell metabolism involves many complex changes in metabolite flux beyond a switch in the amount of glucose metabolized by oxidative phosphorylation and aerobic glycolysis. Understanding how different cancer cells regulate metabolism to achieve a balance between ATP production and biosynthesis is vital for successfully targeting enzymes for cancer therapy. b | Not all tumours exhibit the same metabolic phenotype. Tracer uptake studies in patients and in model systems of cancer have demonstrated that cancer cells exhibit differential uptake of nutrients. This variety is seen even among different tumours that arise from the same normal tissue. This heterogeneity underlies observed differences in 18 F-deoxyglucose positron emission tomography (FDG-PET) and acetate-PET scans in patients, as well as why some tumour cells are 'glutamine-addicted' or exhibit the Warburg effect, and should be considered when stratifying patients for trials using novel therapies that target cancer metabolism.
Cancer cell metabolism
The enzymes and pathways used by cancer cells to transform nutrients into the chemical precursors that make up a cell, and to generate ATP and reducing equivalents that support cellular processes.
LKB1 (also known as STK11), a kinase that is impor tant for AMPK activation in response to metformin 27 , is frequently deficient in human cancers 5 . Thus, the admin istration of metformin to induce energy stress may be par ticularly beneficial for treating LKB1deficient tumours because these cells are unable to activate AMPK and cope with this stress 31 . Planned adjuvant clinical trials of met formin in patients with breast cancer will provide addi tional insight into which patients benefit from metformin. Metformin could also be used as a form of chemopreven tion in patients with a high risk of developing cancer 32, 33 , although the best strategy for identifying individuals to include in such trials has yet to be determined 34 .
Regardless of whether the benefit that is observed with metformin involves a direct effect on cell meta bolism, blocking the signals that link wholebody metabolism to cellular metabolism presents several therapeutic oppor tunities. Antibodies and smallmolecule kinase inhibi tors that target the IGF receptor (IGFR) have been well tolerated by patients 35 . Early studies with these agents have focused on sarcomas, based on preclinical evidence suggesting that these tumours are dependent on IGFR signalling. In fact, some patients with rare sarcomas develop tumourassociated hypoglycaemia that is related to increased production of an isoform of IGF, and dra matic anecdotal responses have been reported in these individuals 36 . Unfortunately, overall these agents have demonstrated limited efficacy in clinical trials, which sug gests that their clinical utility has yet to be determined 35 . Further efforts to identify tumours with altered meta bolism that is dependent on IGFR signalling may enable the selection of patients who could benefit from these therapies. IGFs are thought to increase tumour growth by activating the phosphoinositide 3kinase (PI3K) signa l transduction pathway, which influences metabolic pathways as one downstream consequence of increased signalling 4, 37 . In addition, mammalian target of rapamycin (mTOR) -a major effector downstream of PI3K -is reg ulated by nutrient availability 12 . Activation of mTOR stim ulates a metabolic programme to promote cell growth 38 ; consequently, mTOR inhibitors are increasingly being used in the clinic to treat various cancers, and many compounds targeting the PI3K pathway are in clinical development 39, 40 . A better understanding of how these drugs affect tumour metabolism may define mechanisms of resistance to these agents or identify synergistic targets in metabolism that could convert mTOR inhibitors from cytostatic to cytotoxi c agents and thus increase their efficacy in patients.
Targeting metabolism could improve existing approaches. Many genetic alterations that are known to promote cance r lead to a single converging metabolic phenotype that is characterized by enhanced cellautonomous nutri ent uptake and reorganization of metabolic pathways to support biosynthesis 4, 5, 41 . Growth signalling pathways that are activated in cancer promote these metabolic changes, and compounds that target signal transduction pathways are available in the clinic. However, despite the consider able success of these agents in selective cancers 42 , for many common malignancies it remains a challenge to identify which patients are likely to respond to these drugs.
Interestingly, a decrease in glucose uptake -as meas ured by FDG-PET -has been predictive of a response to compounds that target the PI3K pathway in animal mod els 43 , and of a response to kinase inhibitors in patients 44 . These findings support the hypothesis that a major meta bolic consequence of dysregulated PI3K or tyrosine kinase activation is an increase in nutrient uptake. There is also evidence that increased nutrient uptake is a crucial effect of oncogenic RAS mutations 45 , and therefore decreased nutrient uptake can be predictive of a response to ther apy in KRASdriven lung cancer 43 . This underscores the potential value of FDG-PET as an early predictor of response to molecules that target signalling pathways in the treatment of cancer.
Despite the availability of creative approaches, effective agents targeting many of the common driver mutations in cancer are not available. For instance, mutations in RAS or dysregulated expression of MYC are frequent events in human cancer, yet no specific therapies exist to treat can cers based on either genetic event, and many RASdriven cancers are refractory to existing therapies 46, 47 . Enzymes that are involved in metabolism appear to be key effectors of RAS and MYCdependent pathways. RASmutant cells are dependent on sufficient glucose uptake 45 , and MYC dependent cells have a particular reliance on glutamine metabolism [48] [49] [50] . In preclinical models, targeting metabolic enzymes has been shown to be effective in the treatment of KRASmutant 45, 51 and MYCdependent tumours 52, 53 . For instance, smallmolecule inhibitors that disrupt glucose metabolism can decrease the growth of xenograft tumours that are derived from cells driven by these oncogenes 45, 51, 53 . This suggests that targeting metabolism as an effector of signal transduction pathways that are required for cell growth might be an effective way of targeting cancers that are driven by genetic alterations and cannot be targeted directly. Furthermore, because kinase inhibitor therapies can result in decreased glucose uptake 1, 43 , compounds that further impair glucose metabolism may be synergistic with these approaches. Cytotoxic therapies also compro mise glucose metabolism 54 , so targeting metabolism may sensitize cancers to these drugs as well.
Metabolism is a proven target of successful therapies.
Given that all cancer cells rely on changes in metabolism to support their growth and survival, targeting metabo lism has the potential to affect cancers arising from many different tissues 2 . In fact, the possibility that agents tar geting cell metabolism could be effective across diverse cancer types has historical precedent. For example, anti folate drugs were developed before there was an under standing of how folic acid contributes to a metabolic cycle that allows singlecarbon transfer reactions
, which are critical for the generation of nucleic acids (FIG. 2) . Consequently, the success of antifolate drugs led to the study of other metabolite analogues as potential antican cer agents that disrupt nucleotide synthesis 55, 56 . Today, the antimetabolite class of nucleoside analogues -which includes 5flurouracil, gemcitabine (Gemzar; Lilly) and fludarabine (Fludara; Bayer/Genzyme), along with hydroxyurea and a newer generation of antifolate The use of the enzyme lasparaginase to treat acute lymphoblastic leukaemia (ALL) and related lymphomas is another example of how the unique metabolism of tumour cells has been successfully exploited for cance r therapy. Like antifolate drugs, the potential utility of lasparaginase in treating cancer was discovered by accident and represents another example of rational drug design that was later revealed to exploit a metabolic differ ence between cancer cells and normal cells
. It was found that ALL cells are functional asparagine (and glu tamine) auxotrophs
57
. lasparaginase deaminates aspara gine to aspartic acid, thereby limiting the availability of asparagine for cancer cells (FIG. 3) . The bacterial laspara ginase that is used in the clinic has preferential selectivity for asparagine over the structurally related amino acid glutamine 58 ; however, the enzyme retains some ability to degrade glutamine, and this activity may have a role in the doselimiting coagulopathy caused by the imbalanced synthesis of pro and anticoagulant proteins 58, 59 . However, glutamine is a crucial nutrient for many cancer cells and glutamine depletion may contribute to the effective ness of the drug in ALL 3, 60 . lasparaginase has little utility in the clinic outside of ALL treatment, but other thera peutic uses of this enzyme have not been explored since the early days of chemotherapy.
Glutamine is the most abundant amino acid in serum and a key component of mammalian tissue culture media 60 , and several studies have identified a depend ence of some cancer cells on the nutrient [48] [49] [50] . Thus, lasparaginas e -or analogous agents that are designed to specifically reduce levels of glutamine -may be effective for treating cancers other than ALL. A rational approach to identify other auxotrophies of cancer cells could lead to the development of similar treatment strat egies. Indeed, several types of cancer cells have low lev els of arginosuccinate synthetase, which is required for endogenous arginine synthesis 3 , and early experiments have suggested that tumours may be sensitive to argi nase 61 . Arginine deiminase conjugated to polyethylene glycol (PEG) is an agent that lowers extracellular levels of arginine and is currently in clinical trials for various solid tumours 62 . Early phase (Phase I/II) trials have shown that this drug can be administered safely, and some positive responses have been observed in both hepatocellular car cinoma and melanoma 62, 63 .
Key issues in targeting cancer cell metabolism
Challenges of directly targeting metabolic pathways. Because all cells rely on the same metabolic pathways to generate ATP, it is often assumed that drugs that target metabolic pathways would have detrimental effects on normal tissues. Although this is the case for some meta bolic targets, the success of cytotoxic agents that target folate metabolism and DNA synthesis illustrates that a therapeutic window can exist for anticancer drugs that target metabolic pathways.
These chemotherapies have side effects that are related to ontarget inhibition of the same enzymes in rapidly proliferating normal tissues such as the gut epithelium and bone marrow 64 . The common assumption that the thera peutic window obtained by these agents is due to the more rapid proliferation of cancer cells is not necessarily true. Proliferating cells in the gut have a cellcycle time that is estimated to be 30-40 hours and these cells may prolifer ate as frequently as every 10 hours 65, 66 . Haematopoiesis is also very fast as humans generate 2 million red blood cell precursors per second 67 . Cancer cells can proliferate at similar rates under optimal tissue culture conditions, but most cancer cells proliferate more slowly in vivo 66, 68 . Despite this difference in the rate of proliferation, sensitive cancers can be targeted using these therapies.
Tumour sensitivity to these agents can be accounted for in part by the loss of cell cycle checkpoints that accom pany the transformation of normal cells into cancer cells (chemotherapybased killing mechanisms reviewed in REF. 69 ). However, the fact that folinic acid can selec tively rescue dihydrofolate reductase inhibition in nor mal proliferating tissues (FIG. 2) and enhance the efficacy of 5fluorouraci l in colon cancer therapy 70 suggests that additional metabolic differences exist in cancer cells that also contribute to the therapeutic window. A better understanding of the molecular mechanisms underlying why some cancer cells are more dependent on specific metabolic pathways could result in more effective ways of targeting metabolic pathways, with fewer side effects on normal proliferating cells.
Unwanted toxicity caused by the effects of agents tar geting metabolic pathways in normal proliferating cells is likely to be a major challenge in the development of drugs that target proliferative cell metabolism. Several pathways often exist to generate the same metabolic end product, and redundant pathways that are present in normal cells but absent in cancer cells may provide a therapeutic win dow. However, this same redundancy may also impair the efficacy of drugs in tumours that can use more than one pathway. For instance, the success of targeting ATP citrate lyase as a means of blocking cytoplasmic levels of acetyl CoA is limited in part by the generation of acetylCoA via
Box 1 | The discovery of antifolate drugs as effective anticancer agents
Targeting metabolism has been a prominent feature of some of the first efforts to treat cancer with drugs. Shortly after the discovery of folic acid as a nutrient that is needed to prevent anaemia in pregnancy, Sidney Farber 152 noted that the administration of folic acid conjugates appeared to stimulate leukaemic cell proliferation in patients 56 . This led to one of the first examples of rational drug design as Farber, working with Yellapragada Subbarao and chemists at the Lederle Laboratories, developed the folate analogue aminopterin for use in humans. Aminopterin could antagonize the ability of folic acid to stimulate the growth of bacteria, and this compound was the first drug to induce remission in children with acute lymphoblastic leukaemia 153 . Another folate analogue, methotrexate (amethopterin), replaced aminopterin as the agent used for cancer chemotherapy and resulted in one of the first cures of a solid tumour (choriocarcinoma) by chemotherapy in the late 1950s 154 . Methotrexate was also the first successful adjuvant therapy for osteosarcoma 155 , and is still used for the management of several cancers in the clinic today.
Lactic acidosis
A condition of low blood pH (metabolic acidosis) that is caused by the accumulation of lactate.
another route 71 . Nevertheless, there is mounting evidence that genetic changes that are associated with cancer create addictions to specific metabolic pathways 4, 5 , and cancer cells often have chromosomal deletions that could elimi nate enzymes that are necessary for the use of redundant pathways. Combining agents to target complementary metabolic pathways might therefore be another strategy for reducing the dose of individual drugs and limiting unwanted effects on normal cells.
A therapeutic window does not exist for some targets in cancer metabolism, but drugging alternative targets in the same metabolic pathway may be feasible. Although it has never been used to treat cancer, the mitochondrial uncoupling agent 2,4dinitrophenol (DNP) was used as a weightloss agent in the 1930s 72 . By uncoupling mito chondrial electron transport from ATP synthesis (FIG. 3) , agents like DNP cause energy that is released from nutri ent oxidation to be lost as heat and also induce energy stress in cells. Unfortunately, only slight overdoses of DNP result in lethal hyperthermia. However, metformin also targets oxidative phosphorylation but in a different way (FIG. 3) , is well tolerated and one of the most commonly prescribed drugs in the world. By slowing mitochondrial ATP generation, metformin causes mild cellular energy stress 27 . Metformin has an ontarget, dosedependent side effect of inducing lactic acidosis. Complex I inhibition by metformin decreases mitochondrial oxidation of NADH to NAD + . Regenerating NAD + is necessary to allow con tinued glycolytic flux, and lactate synthesis allows the regeneration of NAD + from NADH in the absence of mitochondrial electron transport. Thus, increased lactate production is an inevitable consequence of increased com plex I inhibition, and this defines the therapeutic window for this class of drugs. However, whether this window is large enough to achieve doses that have direct growth inhibitory effects on tumours in vivo remains to be determined.
Metabolism is often viewed as a housekeeping func tion for cells, whereas signalling pathways are viewed as unique pathways that act only in specific cell types and physiological situations. However, with the exception of gainoffunction mutations, no target is unique to cancer cells. Successful targeted therapies take advantage of the dependence of cancer cells on specific pathways. Similarly, cancer cells depend on specific metabolic pathways, and identifying these dependencies is crucial for generating drugs that can successfully target metabolic enzymes and have minimal effects on normal tissues.
Metabolic flux in cancer cells is not well understood.
Resistance to therapy is an issue with all cancer treat ments, and metabolism is a complex network with builtin plasticity that may allow the cell to overcome inhibition at a single enzymatic step. This further high lights the importance of understanding precisely how metabolic pathways are regulated in cancer cells in vivo. Flux through metabolic pathways, rather than levels of individual pathway metabolites, provides the cell with the ability to continually generate ATP (to support cell sur vival) or crucial biosynthetic precursors (for cell growth). Thus, rather than focusing on levels of individual metab olites, determining flux through the cancer cell metabolic network is likely to provide a better insight into successful enzyme targets.
Recent advances in metabolite profiling methodologies are providing new tools for understanding flux through pathways, and will enhance our understanding of can cer metabolism. Furthermore, increased application of techniques such as magnetic resonance spectroscopy can allow direct visualization of how metabolism is altered in patients as a result of new therapies 73, 74 . These techniques include the use of dynamic nuclear polariza tion to generate hyperpolarized 13 Clabelled metabolites to track metabolism in tumours. These approaches for 
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Metabolite profiling
The measurement of multiple metabolite levels in cells or in body fluid. This is sometimes also referred to as metabolomics. Metabolites are usually detected using nuclear magnetic resonance spectroscopy or mass spectrometry.
tracking metabolism in vivo will be especially vital for understandin g how cell metabolism is influenced by the tumour microenvironment 5 , and will help with the selection of the right patients for specific drugs that target cance r cell metabolism.
Potential of metabolic enzymes as drug targets.
Mutations in oncogenes or tumour suppressor genes result in the addiction of cancer cells to downstream sig nalling events 2, 75 . These genetic events define an ideal set of possible targets for cancer therapy, but unfortunately many of the gene products are transcription factors or signalling molecules that rely on protein-protein inter actions and present challenges to drug development. As a result, efforts have focused on targeting other tractable signalling molecules in a key pathway that is associated with the genetic event. These strategies have had limited success in the clinic, which suggests that blocking single downstream signalling targets is insufficient for inhibit ing the transforming effects of some driver mutations.
Altered expression of metabolic enzymes or changes in the regulation of metabolic pathways also occurs down stream of many oncogenes and tumour suppressor genes, and cancers with specific genetic lesions are addicted to at least some of these metabolic changes 1, 4, 76 . In addi tion, ATP is necessary for the survival of all cells, and the ability to convert nutrients into biomass is crucial for all cance r cells. Thus, attacking metabolism as a down stream consequence of driver mutations is an attractive strategy because it is central to the growth and survival of cancer cells. Furthermore, many metabolic enzymes are amenabl e to targeting with small molecules.
Tumour metabolism can be safely targeted
It is possible to safely target central metabolic pathways in patients. The small molecule dichloroacetate (DCA) is used to treat patients with lactic acidosis resulting from rare inborn errors of mitochondrial metabolism. At least one target of DCA is pyruvate dehydrogenase kinase (PDK) (FIG. 3) . The expression of PDK is increased in many cancers as a result of increased activation of the transcription factor hypoxiainducible factor (HIF) 77, 78 . PDK is a negative regulator of the pyruvate dehydroge nase complex (PDH) 79 . PDH catalyses oxidative decar boxylation of pyruvate to acetylCoA, which allows the entry of pyruvate into the tricarboxylic acid (TCA) cycle and away from lactate production. Thus, DCA mediated inhibition of PDK leads to the activation of PDH, increased meta bolism of pyruvate to acetylCoA and decreased lactate production. DCA can alter the mitochondrial membrane potential and inhibit lactate pro duction in cancer model systems 80 , and has been shown to alter mitochondria in patients with glioblastoma 81 . Importantly, even at doses that influence the mitochon drial membrane potential, DCA is well tolerated by patients 81 . Although there are insufficient data to deter mine whether DCA will provide clinical benefit, these studies demonstrate that a sufficient therapeutic window can exist to target cancer cell metabolism in patients.
Approaches for targeting cancer cell metabolism
Despite a renewed interest in exploring metabolic enzymes as targets for cancer therapy, very few mol ecules that target central carbon metabolism are currently in clinical trials (TABLE 1) . However, mounting evidence 
Mitochondrial membrane potential
The electrochemical proton gradient across the inner mitochondrial membrane that is generated by the mitochondrial electron transport chain. This gradient is used to synthesize ATP and transport molecules across the inner mitochondrial membrane.
Central carbon metabolism
The core metabolic pathways used by cells to generate ATP, reducing equivalents and the main precursors for amino acid, nucleic acid and lipid biosynthesis.
Bioenergetics
A term referring to how energy flows through living systems.
supports several metabolic enzymes as candidate targets, and studies using tool compounds have yielded encourag ing results in preclinical models of cancer. New molecules directed against metabolic enzymes are likely to enter clin ical studies in the next few years. Such compounds have the potential to limit macromolecular synthesis needed for cell growth, a strategy that is employed by existing drugs that target nucleic acid synthesis. Alternatively, tar geting metabolism can limit pathways that are important for supplying nutrients to the cell and impair bioenergetic s, thus preventing an adaptive response to cell stress. This latte r approach is more likely to be synergistic with non metabolic therapies that also impair nutrient uptake 54 . Enzyme targets that fall into both classes are summarized in TABLE 1 .
These approaches could have seemingly opposite effects on some metabolic phenotypes. For instance, both DCA and metformin target mitochondrial physiol ogy, yet DCA decreases lactate production and is used to treat lactic acidosis, whereas metformin increases lactate production and lactic acidosis is an important side effect of metformin treatment. Although paradoxical, there is evidence to suggest that both drugs are potentially ben eficial in cancer treatment. By increasing glucose entry into the TCA cycle, DCA directs carbon away from lactate production 80 (FIG. 3) and, as a consequence, it may direct metabolism away from efficient biosynthetic reactions 1 . Conversely, metformin inhibits the transfer of electrons from NADH in the mitochondria to the electron trans port chain (FIG. 3) . This increases reliance on lactate pro duction as a means to regenerate NAD + from NADH, impairs mitochondrial production of ATP and causes cellular energy stress 26, 31 . Both approaches to impair meta bolism could have therapeutic benefit in the right context. The former strategy (DCA) is likely to be more effective in tumours with increased reliance on high glucose uptake and lactate production, whereas the latter strategy (met formin) might synergize with other therapies that induce energy stress.
Directly targeting glucose metabolism. Various agents have been shown to block glucose uptake by cancer cells, but so far no specific glucose transport inhibitors have been reported. Glucose transporter 1 (GLUT1; also known as SLC2A1) is the glucose transporter with the largest tissue distribution and is thought to be responsible for basal glucose uptake in most cancer cells and normal cells 82, 83 (FIG. 3) . Although GLUT1 is expressed at much higher levels in cancer cells than in normal cells, it may be difficult to directly inhibit glucose uptake in tumours without having an effect on normal tissues. Nevertheless, partial inhibition of glucose uptake may still sensitize can cer cells to other drugs (reviewed in REF. 84 ).
Many of the studies exploring glucose dependence rely on the withdrawal of glucose from cells in culture, which illustrates the need for pharmacological agents that inhibit glucose uptake. There are at least thirteen passive glucose transporters, most of which have poorly understood functions. Interestingly, some of these, such as GLUT3 (also known as SLC2A3), are not expressed in most normal cells but they can be expressed at high lev els in cancer cells, which suggests that these transporters could be possible therapeutic targets 82 . Antibodies that selectively target GLUT3 or other nutrient transporters with restricted expression may represent another way of blocking nutrient uptake and starving cancer cells.
2deoxydglucose (2DG) is an inhibitor of glucose metabolism as it is phosphorylated in cells by hexoki nase to produce 2deoxyglucose6phosphate, which is a competitive inhibitor of enzymes that metabolize glucose6phosphate. Cells that are exposed to sufficient amounts of 2DG undergo growth arrest and/or apop tosis 85 , and 2DG may potentiate the effects of standard cytotoxic chemotherapy 84, 86 . 2DG has been tested as an anticancer agent in patients 87 , but when it was admin istered to patients with glioblastoma at doses that were sufficient to limit glucose metabolism in cancer cells, unacceptable toxicity was observed 88, 89 . Lower doses of 2DG are better tolerated by patients, but limited efficacy has been observed at these doses 90 . However, because 2DG is a competitive inhibitor of glucose, and glucose is present at millimolar concentrations in the blood, it remains to be determined whether a sufficient therapeutic window exists to competitively inhibit glucose uptake or the downstream enzymes in glycolysis.
It appears that cancer cells preferentially rely on spe cific isoforms of glycolytic enzymes. Therefore, isoform selective targeting may provide an alternative approach for modulating glucose metabolism in cancer cells. Hexokinase is responsible for trapping glucose in cells (FIG. 3) and at least some cancers are specifically depend ent on the hexokinase 2 (HK2) isoform of this enzyme 91, 92 . HK2 is normally expressed in skeletal muscle and adipose tissue, which provides a therapeutic window to target HK2 without risking ontarget side effects in other nor mal tissues that express another isoform. The properties of HK2 that select for its expression over other hexokinase isoforms in cancers are not clear. Nevertheless, the fact that HK2 is specifically required by some cancers sug gests that reexpression of another hexokinase isoform is unlikely to provide an escape mechanism for tumours that are treated with an HK2selective inhibitor.
An association between hexokinase and mitochondria influences the regulation of apoptosis 93 , and compounds isolated from plants that disrupt this association are toxic to cancer cells in culture 94 . Hexokinase is also a target of 3bromopyruvate, a compound that has been shown to
Box 2 | Development of l-asparaginase to treat ALL
The potential utility of l-asparaginase in the treatment of cancer was first discovered when it was noted that guinea pig serum, but not the serum of other animals, had an inhibitory effect on the proliferation of lymphoma cells in mice 156 . Guinea pigs are unique among mammals as their serum has l-asparaginase activity 157 , and this l-asparaginase activity was found to be responsible for the antilymphoma effect that was observed in mice 55, 158 . l-asparaginase was found to be a particularly effective agent in the treatment of acute lymphoblastic leukaemia (ALL) and associated high-grade lymphomas, and it induced remission as a single agent in more than 50% of children with the disease 159 . Although these remissions were not durable, when l-asparaginase has been used as part of a combination chemotherapy regimen, it has contributed to a >80% cure rate for children with ALL, and its inclusion in adult chemotherapy regimens has contributed to improved clinical outcomes 160 . α be toxic to cancer cells 91, 95 . However, 3bromopyruvate is also toxic to some cancer cells at concentrations that are too low to inhibit hexokinase; it has therefore been argued that the combined inhibition of several metabolic enzymes accounts for the toxic effects of this compound on cancer cells 96 . Pyruvate kinase is another glycolytic enzyme for which isoformselective targeting may be therapeutically beneficial (FIG. 3) . There are two pyruvate kinase genes in mammals, and both produce two distinct gene products by alternative splicing 97, 98 . Most tissues express a product of the pyruvate kinase M (PKM) gene that is alternatively spliced to produce either the PKM1 or PKM2 isoform. All cancer cells express PKM2, whereas many differen tiated tissues express PKM1 (REF. 97 ). The expression of PKM2 promotes aerobic glycolysis, and PKM2 expres sion is selected for during growth of xenograft tumours in mice 99 . PKM1 is a constitutively active enzyme, whereas Figure 3 | Targeting metabolic enzymes as a strategy to block biosynthesis or induce energy stress. The pathways of central carbon metabolism are presented. Some of the metabolic enzymes that are currently being considered as therapeutic targets for cancer are marked with a target (shown as a pink circle in the figure). Five drugs that influence metabolism and have been tested in humans are shown in pink boxes. This figure illustrates how these enzyme targets are involved in the synthesis of important macromolecules (shown in brown boxes) that are needed for cell growth. αKG, α-ketoglutarate; DCA, dichloroacetate; DNP, 2,4-dinitrophenol; F-2,6-BP, fructose-2,6-bisphosphate; F6P, fructose-6-phosphate; FBP, fructose-1,6-bisphosphate; G6P, glucose-6-phosphate; GLS, glutaminase; GLUT1, glucose transporter type 1; HK2, hexokinase 2; I, complex I; IDH, isocitrate dehydrogenase; III, complex III; IV, complex IV; LDH, lactate dehydrogenase; MCT4, monocarboxylate transporter 4; OAA, oxaloacetate; PDH, pyruvate dehydrogenase complex; PDK, pyruvate dehydrogenase kinase; PEP, phosphoenolpyruvate; PFK1, phosphofructokinase 1; PFK2, phosphofructokinase 2; PKM2, pyruvate kinase M2 isoform; V, complex V.
PKM2 is unique among pyruvate kinase isoforms in that its enzyme activity is inhibited following its binding to tyrosinephosphorylated proteins downstream of cellular growth signals 100 . Surprisingly, it is this ability to inhibit the PKM2 enzyme that appears to be important for the promotion of aerobic glycolysis and cell proliferation in tumours.
Selection for a less active form of pyruvate kinase may help to divert glucose metabolites upstream of pyruvate kinase into biosynthetic pathways 5, 97, 100 . Efforts have been made to selectively inhibit PKM2 (REFS 101, 102) . Peptide aptamers that promote the less active form of pyruvate kinase have been shown to cause energy stress and cell death in cultured cancer cells 101 , and more modest effects were observed using smallmolecule inhibitors of PKM2 (REF. 102 ). Targeting PKM2 with short hairpin RNA can slow cell proliferation in cell culture 99 ; however, these cells retain the ability to proliferate even in the nearcomplete absence of pyruvate kinase activity. These findings suggest that the activation of PKM2 to restore the high activity state of pyruvate kinase found in normal tissues may be an alternative strategy for targeting pyruvate kinase in cancer.
Isoformspecific smallmolecule activators of PKM2 have been reported 103, 104 . However, whether these com pounds can induce the same growth disadvantage in vivo that is observed in PKM1expressing cells remains to be determined. PKM2 is unique among pyruvate kinase isoforms as it has the ability to switch between a low and high activity state; therefore, it is possible that disrupting this dynamic capability with either enzyme inhibitors or activators could be therapeutically beneficial in cancer. However, PKM2 is also expressed in many normal tis sues 97 , and it remains to be determined whether the acti vation or inhibition of PKM2 in these tissues will result in unacceptable toxicity.
Another example of a regulatory enzyme in gly colysis with isoform selectivity in some cancers is phosphofructokinase 2 (PFK2) (FIG. 3) . By generating fructose2,6bisphosphate (F2,6BP), PFK2 activates phosphofructokinase 1 (PFK1) to increase flux through this step of glycolysis. Most isoforms of PFK2 are bifunc tional enzymes with both kinase and phosphatase activ ity, and can therefore also catalyse the destruction of F2,6BP and decrease PFK1 activity 105 . The FB3 isoform of PFK2 (PFKFB3) is expressed in many cancers and is required for anchorageindependent growth of RAS driven tumours 106, 107 . PFKFB3 has almost no phosphatase activity, and its kinase activity is influenced by several factors that are implicated in controlling cancer meta bolism, including metabolite levels as well as RAS, MYC and AMPK signalling 105, 108, 109 . Smallmolecule inhibitors of PFKFB3 have been reported to have a cytostatic effect on RAStransformed cancer cells 51 . The compound tar geting PFKFB3 decreases levels of F2,6BP and impairs the growth of xenograft tumours 51 , thus raising interest in this enzyme as a target for cancer therapy.
Inhibiting lactate production or transport. Because lac tate is excreted from the cell, inhibiting lactate production or lactate transport out of the cell are two strategies that directly target the Warburg effect in cancer. The family of monocarboxylate transporters (MCTs) comprises the major proteins that are responsible for lactate export in glycolytic cells, including cancer cells [110] [111] [112] (FIG. 3) . There is evidence that a symbiotic relationship exists among dif ferent cells within a tumour whereby some cells rely on the lactate produced by other cells as a fuel source, and so disrupting lactate transport can starve cells that are dependent on lactate for survival 113 . However, targeting MCTs using small molecules also inhibits the prolifera tion of lymphocytes that rely on aerobic glycolysis 114, 115 . This suggests that impaired immune function could be a side effect of targeting lactate export in cancer, and that drugs targeting cancer metabolism may have applications as immunosuppressive therapies.
Additional potential side effects of inhibiting lactate transport include negative effects on other normal tissues -such as the liver, muscles and brain -that rely on lac tate as a fuel in certain physiological situations 116 . Lactate dehydrogenase (LDH) is the enzyme that interconverts pyruvate and NADH with lactate and NAD + , respectively (FIG. 3) . When LDHA is knocked down using RNA inter ference, cancer cell proliferation is severely impaired both in vitro and in vivo 52, 117 . LDHA is the form of LDH that is expressed in many cancer cells, and inhibitors of this enzyme are being developed. Most noncancerous tissues are not dependent on LDHA, and LDHA can be selec tively inhibited over other forms of LDH 118 . Furthermore, LDHA inhibitors slow the growth of xenograft tumours in mice and can induce tumour regression when they are combined with nicotinamide phosphoribosyltransferase (NAMPT) inhibitors 53 , which indicates that LDHA could be a promising therapeutic target for cancer therapy.
Targeting NAD + metabolism. Cells possess a limited pool of NAD + and NADH, yet these molecules exist as important cofactors in metabolic oxidation-reduction reactions. They are also substrates for enzymes such as NADdependent deacetylase sirtuins and poly(ADP ribose) polymerases that are involved in the regulation of numerous processes related to cancer, including DNA repair, inflammation and protein acetylation 119 . Unlike oxidation-reduction reactions, these latter reactions con sume NAD + and deplete the cellular pool of this impor tant cofactor.
Interestingly, NAMPT, the enzyme that is involved in regenerating NAD + from nicotinamide and phosphori bosyl pyrophosphate via a salvage pathway, was identified as the target of a molecule that was discovered in a screen to find novel cytotoxic compounds 120 . Cells that are treated with NAMPT inhibitors die as a result of NAD + depletion, and NAMPT inhibition has shown activity as an anticancer agent in preclinical models of cancer 119 . Because NAD + is a required cofactor for the step of glycolysis that is catalysed by glyceraldehyde3phos phate dehydrogenase, cells must regenerate NAD + from NADH to enable the continued flow of glucose carbon via glycolysis (FIG. 3) . Consistent with NAMPT inhibitors limiting glucose metabolism in cells with a high activity of NAD + consuming enzymes, NAMPT inhibition in cells primarily has an effect on the cytosolic rather than the mitochondrial NAD + pool 121 . NAMPT inhibition can 
Metabolic flux
The rate by which molecules flow through a metabolic pathway. Flux through metabolic pathways is regulated by cells to support cellular processes, and is the composite outcome of: enzyme levels; genetic, allosteric and post-translational regulation of enzymes; and concentrations of metabolites.
Anapleurosis
A term describing the requirement of metabolites to replenish a metabolic cycle when the metabolic intermediates that are involved in the cycle are depleted for use in reactions outside the cycle. The classic example of this process is replenishing those intermediates that are depleted from the tricarboxylic acid cycle for biosynthesis, in order to allow the cycle to continue functioning.
Redox state
A term capturing the reduction-oxidation state of a system. For cells this refers to the propensity of redox couples -such as reduced and oxidized glutathione or NADH and NAD + -to be in one state or the other.
also be toxic to lymphocytes 122 , which suggests that the use of NAMPT inhibitors in patients might be limited by immunosuppression. Mild lymphopaenia was observed in early clinical trials of NAMPT inhibitors, but throm bocytopaenia was the doselimiting toxicity 123 . Limited clinical efficacy has been observed so far with NAMPT inhibitors, although there is ongoing research to develop more potent compounds and define those patients who are most likely to benefit from NAMPT inhibition 124 .
Targeting metabolic enzymes that are mutated in cancer. The idea that metabolic alterations are not the same across all cancers is supported by the discovery of a novel metabolic flux that is dictated by mutations in isocitrate dehydrogenase (IDH). Point mutations in isoci trate dehydrogenase 1 (IDH1) and IDH2 that are found in cancer always involve a residue in the active site of only one allele [125] [126] [127] , and lead to the production of d2hydrox yglutarate (2HG) -a metabolite that is only found at very low levels in normal cells [128] [129] [130] . Mutations in IDH define a clinically distinct subset of both glioma and leu kaemia, which suggests that these mutations contribute to a unique biology within each tumour type 125, 127, 131, 132 . It is not clear how mutations in IDH and the produc tion of 2HG promote cancer, nor is it clear whether exist ing cancers remain dependent on the abnormal enzyme activity; however, 2HG is an inhibitor of αketoglutarate (αKG)dependent dioxygenases [133] [134] [135] . αKGdependent dioxygenases are involved in an oxygensensing path way that leads to the stabilization of the HIF transcrip tion factor, which controls the expression of many genes that have an important role in cancer progression and metabolic regulation 10, 11 . αKGdependent dioxygenases are also involved in demethylation reactions that affect chromatin structure, and they have pleiotropic effects on global transcription and cellular differentiation 136, 137 ; this methylation pattern is altered in cells with IDH mutations 133, 134 . Thus, the development of small mol ecules that inhibit the production of 2HG by mutated IDH may restore normal αKGdependent dioxygenase function and normalize both HIF levels and chromatin structure. In addition, because αKGdependent dioxy genases are influenced by the αKG/succinate ratio, the delivery of αKG analogues may be another way to restore normal dioxygenase activity. These cellpermeable esters of αKG can increase both αKG levels and dioxygenase activity 138 . This latter strategy to increase αKG has shown some success in models of human cancer with abnormal αKG/succinate ratios that are caused by lossoffunction mutations in succinate dehydrogenase or fumarate hydratase 138 .
Additional strategies for targeting glutamine metabolism. As discussed above, glutamine is an important nutrient for some cancer cells. Glutamine is the major source of nitrogen for nucleotide and amino acid synthesis, but many cells metabolize glutamine in excess of their nitro gen requirement. Glutamine also has an important role in replenishing intermediates of the TCA cycle that are depleted by biosynthetic reactions 139 (anapleurosis) (FIG. 3) . The enzyme glutaminase catalyses the conversion of glutamine to glutamate in a pathway involved in produc ing αKG. Glutaminase has two major isoforms in mam mals, glutaminase 1 (GLS1) and GLS2, and the expression of these enzymes can have opposite effects on cell prolif eration 140 . GLS1 is an important downstream effector of MYC and promotes the entry of glutamine into the TCA cycle 49, 50 , whereas GLS2 is regulated by the tumour sup pressor p53 and influences the cellular redox state 141 . These different functions of GLS1 and GLS2 are likely to have key roles in cancer metabolism, and the growth of transformed cells can be selectively inhibited by targeting glutaminase activity 142, 143 . Blocking GLS1 activity can prevent the entry of glutamine into cells as a source of 2HG production by mutated IDH1, and can therefore slow the growth of these cells 143 . GLS1 has also been identified as the target of a molecule that blocks cell transformation by RHO GTPases; this molecule can slow the growth of RHO GTPasetransformed fibroblasts and breast cancer cells 142 . However, lymphocytes are also dependent on glutamine metabolism 144 , which suggests that immunosuppression may be a side effect of drugs that target glutamine metabolism for cancer therapy.
Targeting other metabolic dependencies in cancer cells.
Therapies that target cancer metabolism should attack those metabolic pathways that meet the specific needs of cancer cells. This approach is analogous to targeting nucleic acid metabolism with antimetabolites, but need not be limited to approaches that interfere with DNA replication. Many cancer cells rely on de novo fatty acid synthesis to generate new membranes for cell growth, and the enzymes that are directly involved in fatty acid synthesis have been suggested as cancer targets 145, 146 . Lipids also have important signalling functions in cells, and chemical genetic screens have identified lipases that release fatty acyl chains from glycerol as therapeutic tar gets in some cancers 147 . However, it remains to be deter mined whether targeting lipid synthesis to alter signal transduction or to structurally interfere with cell growth will have a better therapeutic index.
NADPH is the major cofactor carrying electrons for reductive biosynthesis and must constantly be regener ated from NADP + to maintain reducing conditions in the cell and feed biosynthetic reactions. Targeting the major sites of NADPH production in cancer cells could limit biosynthesis and lead to cellular damage by pro moting a more oxidizing intracellular environment 1 . The pentose phosphate pathway is a source of NADPH production and may represent a target for cancer ther apy 148 . However, decreased NADPH production via the pentose phosphate pathway is a characteristic of patients with glucose6phosphate dehydrogenase deficiency, and this deficiency has not been found to be protective against cancer 149 . Furthermore, some cancers do not have a large pentose phosphate pathway flux 150 . Cells can gen erate NADPH via other pathways, and malic enzymewhich can be involved in the conversion of glutamine to lactate -has been suggested both as a therapeutic target and a major source of NADPH in glioblastoma cells 139 .
Whether there are other targets that are important for NADPH generation remains to be determined.
Conclusions and future directions
It is clear that instead of a single tumourspecific metabo lism, several metabolic programmes exist to support the proliferation of cancer cells. This may explain why current antimetabolite chemotherapies that target DNA synthesis are efficacious in some cancers but not in others, despite the need for all tumour cells to synthesize nucleotides. It may also highlight why a therapeutic window exists for these agents despite the fact that the same pathways are required in normal proliferating cells. A better under standing of how metabolism is altered in specific genetic contexts that lead to cancer will provide an insight into which enzymes -or combination of enzymes -repre sent promising targets in certain cancers, and this under standing will arise from an analysis of cancer metabolism that extends beyond the levels of expression of various enzymes in a metabolic pathway.
Despite the success observed by targeting enzymes that are involved in nucleotide synthesis, efforts to tar get other enzymes and pathways involved in cellular metabolism are in their infancy. As targets become bet ter defined, targeting these enzymes could result in the delivery of effective therapies that spare normal tissues but effectively target cancer tissues. Structural informa tion, together with a basic understanding of enzyme properties, already exists for many potential targets in metabolism. Building a conceptual framework to under stand metabolic regulation in cancer, however, remains a challenge for the development of successful therapies. Efforts to model human metabolism and select rational target combinations are ongoing 151 . Complementing these models with a more complete understanding of pathway biochemistry in cancer cells will help to determine the best targets for possible intervention. The development of new methods to study tumour metabolism in vivo will be crucial. Ultimately, these efforts will determine whether a sufficient therapeutic window exists to spare normal tis sues from unwanted toxicity and whether further inves tigation of the anticancer potential of agents that target these enzymes is warranted.
